Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2233-2237

  Hoskins, P ^a   Eisenhauer, E ^a   Beare, S ^a   Roy, M ^a   Drouin, P ^a   Stuart, G ^a   Bryson, P ^a   Grimshaw, R ^a   Capstick, V ^a   Zee, B ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 0031781459     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2233     Document Type: Article

References (18)

1. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Long term survival in ovarian cancer. Eur J Cancer 27:1367-1372, 1991
2. Hoskins PJ, O'Reilly SE, Swenerton KD, et al: Ten year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 10:1561-1568, 1992
3. Sutton GP, Stehamn FB, Einhorn LH, et al: Ten year follow up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223-229, 1989
4. Hainsworth JD, Grosh WW, Burnett LS, et al: Advanced ovarian cancer: Long term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 108:165-170, 1988
5. Kudelka A, Tresukosol D, Edwards C, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
6. Carmichael J, Gordon A, Malfetano J, et al: Topotecan, a new active drug vs paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group. Proc Am Soc Clin Oncol 15:A765, 1996 (abstr)
7. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
8. Gordon A, Bookman M, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group. Proc Am Soc Clin Oncol 15:A763, 1996 (abstr)
9. Armstrong D, Rowinsky E, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:A769, 1995 (abstr)
10. Burris H, Kuhn J, Johnson R, et al: SKF 104864. Preclinical studies of a new topoisomerase I inhibitor. Proc Am Assoc Cancer Res 31:431, 1990 (abstr)
11. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24 hour continuous infusion. Cancer Res 54:1220-1226, 1994
12. Hoskins PJ, Eisenhauer E, Beare S: Randomized phase II study of 2 schedules of topotecan in previously treated patients with epithelial ovarian (EOC). Eur J Gynecol Oncol 18, A179, 1997 (abstr)
13. Van der Burg MEL, Myles JD, Hoskins P, et al: CA 125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. Eur J Cancer 29A:8133, 1993 (suppl 16, abstr)
14. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381, 1985
15. Markman M, Hoskins W: Response to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992
16. Eisenhauer EA, Vermorken JB, Van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: An analysis of 704 patients. Ann Oncol 8:963-968, 1997
17. Hochster H, Speyer J, Wadler S, et al: Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion. Ann Oncol 7:69, 1996 (suppl 5, abstr)
18. Johnson S, Pyle L, King K, et al: A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma. Eur J Cancer 33:S120, 1997 (suppl 8, abstr)